Long-term Efficacy and Tolerance of Tacrolimus for the Treatment of Uveitis

Hogan, Aideen; McAvoy, C E; Dick, Andrew D.; Lee, Richard W.

doi:10.1016/j.ophtha.2007.01.026

Cited by 112 publications

(54 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over the last few years, assisted by major expert opinion overview articles that provided treatment recommendations, 49 there have been further seminal trials and patient cohort studies highlighting the evidence for treatment with non-biologic conventional immunosuppressants. 4,7,[50][51][52][53][54][55][56][57][58] The most compelling studies of recent years include evidence from patient cohort analytical studies for the use of cellcept displaying its effectiveness as a corticosteroid-sparing agent with an acceptable adverse event profile. 4,7,59 In particular, there are two studies that presented their results in accordance with SUN guidelines showing concordance in effect, with around an 80% chance of achieving disease control at a prednisolone dose of o10 mg/day.…”

Section: Treatment Outcomes To Datementioning

confidence: 99%

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Lee

Dick

2011

Eye

View full text Add to dashboard Cite

The blockbuster drug paradigm is under increasing scrutiny across the biopharmaceutical industry. Intraocular inflammation poses particular challenges to this, given the heterogeneity of conditions in the uveitis spectrum, and the increasing acknowledgement of individual patient and disease variance in underlying immune responses. This need has triggered a drive towards personalised and stratified medicine, supported and enabled as a result of continued development of both experimental models and molecular biological techniques and improved clinical classification. As such we have the ability now to systematically appraise at a genomic, transcriptomic, and proteomic level individual immunophenotype, and the promise that in the eye this can be augmented by in vivo immune imaging to identify individual immunopathology. With such advances all running in parallel, we are entering an era of experimental medicine that will facilitate early diagnosis, generate biomarkers for accurate prognostication, and enable the development of individualised and targeted therapies, which can progress rapidly into clinical practice.

show abstract

Section: Treatment Outcomes To Datementioning

confidence: 99%

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Lee

Dick

2011

Eye

View full text Add to dashboard Cite

show abstract

“…Systemic and topical use of tacrolimus is established in ophthalmologic treatments of immune-mediated diseases [6,14,[17][18][19][20][21][22], uveitis [23,24], graft-versus-host disease [25,26], corneal transplants [8,[27][28][29][30], and ocular pemphigoid [31]. In veterinary medicine, topical tacrolimus aqueous suspension is a wellestablished treatment for dry eye in dogs [32,33].…”

Section: Introductionmentioning

confidence: 99%

Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study

Moscovici

Holzchuh

Sakassegawa-Naves

et al. 2015

Contact Lens and Anterior Eye

View full text Add to dashboard Cite

“…Duration of treatment is usually 18-24 mo of inactive eye off steroid drops. Other immunosuppressive agents like azathioprine [26], mycophenolate mofetil (MMF) [27] and calcineurin inhibitors [28,29] can also be tried, however experience with these drugs is not so vast. Doycheva et al have shown a beneficial steroid sparing effect in 88% children with uveitis on MMF with resultant complete withdrawal or significant reduction in dose of steroids in their cohort of 17 children with uveitis [27].…”

Section: Treatmentmentioning

confidence: 99%